
Glaucoma
Latest News
Video Series

Latest Videos
Shorts










Podcasts
CME Content
More News

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

Optometrists should know what is expected, what is concerning, and when to contact the surgeon.

The latest in drug and technology developments and updates from August 2026.

Catch up on the top stories in optometry during the week of August 24-28.

The agency assigned a PDUFA target action date of April 30, 2027.

The primary outcome of the trial is intraocular pressure (IOP) measured using Goldmann Applanation Tonometry (GAT).

Glaukos finishes US pivotal enrollment for Preserflo MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

A large real-world cohort study by Takashi Nishida, MD, PhD et al finds OSA is associated with elevated glaucoma risk.

ZEISS partners with Envision to expand evidence-backed VR perimetry, enabling more accessible, gamified home visual field testing for glaucoma monitoring.

Preservative-free bimatoprost gel now offers once-daily glaucoma and ocular hypertension IOP reduction, aiming to boost comfort, tolerability, and long-term adherence.

The emerging technology offers a new paradigm for treating a group of eye diseases.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

AI models show promise but face significant hurdles in predicting glaucoma progression, review finds
The review analyzed 46 reports from 43 unique studies.



























